BD – BDX – Announces Agreement to Acquire Safety Syringes, Inc.


BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it has entered into a definitive agreement to acquire Safety Syringes, Inc., a privately held California-based company that specializes in the development of anti-needlestick devices for prefilled syringes. The acquisition, which is subject to the satisfaction of customary closing conditions, including regulatory approvals, is expected to close by the end of BD’s fiscal year 2012. The financial terms of the agreement were not disclosed.

The acquisition would enable BD to provide passive safety offerings to any prefillable syringe customer. Safety Syringes, Inc. is a category leader for passive needle shields and guards for prefilled syringes, currently supporting more than 20 drugs on the market.

“This pending acquisition is well aligned to BD’s strategy of applying technology and clinical knowledge to make healthcare more effective, efficient and safe. Developments for parenteral drug delivery systems continue to be a part of BD’s long-term strategy,” said William A. Kozy, BD Executive Vice President. “This acquisition is intended to provide our BD Medical – Pharmaceutical Systems unit with additional safety features for prefillable syringes, helping to protect against accidental needlesticks by providing safer injections for healthcare workers and end users.”


Safety Syringe, Inc.’s UltraSafe® Passive products are specifically designed for prefillable syringes. Using innovative passive protection, these products provide a drug delivery system with a safety guard that passively (automatically) locks into place, delivering easy-to-use injury protection and safety.

“We believe BD’s prefillable syringe expertise, combined with Safety Syringes’ product portfolio and device development expertise, will enable new and innovative safety technology development to prepare the next generation of safety-engineered prefillable syringes,” said Claude Dartiguelongue, President, BD Medical – Pharmaceutical Systems.

BD expects the transaction to be minimally dilutive for fiscal year 2012, and does not expect it to impact BD’s previously communicated 2012 earnings guidance.

About BD – BDX

BD (BDX) is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people’s health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

More Posts by this author


edliston
Post Written By: Ed Liston
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.

Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...